Deinove

Pr Gérard Goma, professor emeritus, INSA, Toulouse

Gerard Goma graduated as an Engineer (Industrial Chemistry) and PhD in Bioengineering from INSA Lyon, France and is an expert in chemistry, petrochemistry, industrial microbiology, enzymology, & in eco-technologies. Gérard Goma has an extensive experience including being a professor and researcher at INSA Toulouse (France) since 1966, developing the Biofood Engineering Department at INSAT, heading the Biotechnologies and Bioprocesses Laboratory and developing technology transfer activities. In parallel, he has had several assignments for the French Government and in industry, including responsability for the diversification at St Gobain in Biotechnology, and member of the Technological Advisory Board at Rhône Poulenc. Gérard Goma authored over 180 scientific publications. He regularly takes part in international expertise missions as a UN expert in chemical and biological defense. His current research focuses on innovation and technology transfer, a systemic holistic approach to microbiology and the synergies between the different applications of biotechnology. From the socio-economic perspective, he is notably working on green-house gases, the carbon tax, food vs. fuel competition and biofuels.

Pr Miroslav Radman, Director of Unit 571 « Evolutive and Medical Molecular Genetics» - INSERM (National Medical Research Institute)

Miroslav Radman, was born in Split (Croatia) and holds dual French and Croatian citizenship. He was awarded a PhD in Sciences from the Université libre de Bruxelles (Belgium) and has since held several positions as Professor at the Université libre de Bruxelles (1973-1983) - NIH (USA) as a visiting Professor - Paris René Descartes University and Faculty of Medicine/Necker- Children's Hospital - He is also Director of Research at the CNRS (National Center for Scientific Research) and founder of MedILS (Mediterranean Institute for Life Sciences) in Split (Croatia). Member of the Bioethics Committee of UNESCO. Miroslav Radman has co-founded 4 biotech companies. He is a member of the Board of Axa Research Fund and a Scientific Advisor to the Prime Minister of Croatia. Miroslav Radman has authored 191 scientific articles (cited over 10.000 times) and is an inventor of 7 patents. As a specialist in DNA mutation and repair mechanisms, one of his most spectacular discoveries was the molecular mechanism of speciation. He has also explained the cause-effect relationship between mutations and cancer.

Pr Patrick Forterre, Professor at Paris-Sud 11 University, Member of the Institut Universitaire de France, Director of the Microbiology Department, Pasteur Institute

From 1972 to 1978, Patrick Forterre worked as a researcher at the Jacques Monod Institute in Paris. PhD in Biochemistry in 1985 he words from 1985 to 1988, as a researcher at the Cancer Research Institute, CNRS, Villejuif.
Patrick Forterre has always thought that the knowledge of the orin and and evolution of molecular mechanisms is important for understanding the latter's mechanism. He soon became convinced of the importance of the "Archaebacteria" concept (proposed by Carl Woese in 1977) and has worked since 1983 on the molecular biology of micro-organisms. His team at the Orsay Microbiology and Genetics Institute (Université Paris-Sud) has discovered a new family of archael DNA topoisomerases type II, which enabled identification of the protein that initiates genetic recombination in eukaryotes. In 2004, Patrick Forterre also founded at the Pasteur Institute a laboratory working on viruses that infect Archaea from hot thermal waters.

Florence Lazard, expert in intellectual property, Semaphore Consulting

Florence Lazard founded Semaphore Consulting after having headed the Institut Curie's Technology Transfer and Licensing Department. She has spent 10 years in academic research, 3 years in pharmaceutical R&D, and 25 years in licensing, business development and technology transfer in academic institutions, in industry and as a patent attorney. She has a PhD in the Biological Sciences and is registered as a qualified person in intellectual property, and as an expert attached to the Paris Court of Appeal.

Ivan Matic, Director of Research CNRS, U571 INSERM, Faculty of Medicine, Paris-Descartes University

Born in Split (Croatia), Ivan Matic is a Biology Engineer (University of Zagreb, Croatia) and a PhD in Sciences, Cell and Molecular Genetics (University Paris-Sud Orsay, France). Ivan Matic studies the evolutive and molecular mechanisms that control recombination and mutagenesis in bacteria, this allowing to understand the rapid evolution of resistance to antibiotics and of the virulence. Another subject of his research is the molecular mechanisms involved in the generation of individual phenotypic variability and in ageing, in the Caenorhabditis elegans model. This fundamental research work could serve the development of therapies for cancer and ageing-relating diseases.

Pr Pierre MONSAN, INSA Toulouse, Institut Universitaire de France

Né le 25 juin 1948 à Prades (66), France, le Professeur Pierre Monsan est ingénieur diplômé du Département de Génie Biochimique et Alimentaire de l'Institut National des Sciences Appliquées de Toulouse (1969). Il a effectué depuis 1969 une carrière d'enseignant-chercheur dans ce même Département, où il a préparé et obtenu une thèse de Docteur- Ingénieur (1971) et une thèse de Docteur d'Etat (Université de Toulouse, 1977), sous la direction de Gilbert Durand. En 1981, il a obtenu un poste de Professeur à l'INSA de Toulouse, responsable du Laboratoire de Catalyse Enzymatique. Il est également Professeur à l’Ecole des Mines de Paris (option Biotechnologie) et membre senior de l’Institut Universitaire de France (Promotion 2003, renouvelé en 2008). En 1984, Pierre Monsan s’est impliqué, comme co-fondateur, dans la création de la société BioEurope. Il a également participé à la création des sociétés Biotrade (Toulouse, 1996) et Génibio (Toulouse, 1998), et à l’implantation de la société LibraGen à Toulouse (2004), dont il est vice-président du Conseil de Surveillance. Il a développé plusieurs procédés industriels de biocatalyse. Il préside le Comité Consultatif Régional pour la Recherche et le Développement Technologique (CCRRDT) du Conseil Régional Midi-Pyrénées. Il est le créateur du Pôle Aliment-Santé Midi-Pyrénées, regroupant 14 laboratoires de recherche et 17 entreprises. Il est président du Groupe Français des Glucides de la Société Française de Biochimie et Biologie Moléculaire et président du conseil scientifique de l’Institut français des boissons, de la brasserie et de la malterie (IFBM, Nancy). Pierre Monsan est membre fondateur de l'Académie des Technologies. Il s’est vu décerner le Prix Chaptal 2000 des Arts Chimiques par la Société d’Encouragement pour l’Industrie Nationale. Il est Officier dans l’ordre des Palmes Académiques. Il est actuellement responsable de l’axe Biocatalyse du Laboratoire d’Ingénierie des Systèmes Biologiques et des Procédés (UMR CNRS 5504 ; UMR INRA 792) de l’INSA de Toulouse et anime une équipe de 55 personnes dans le domaine de la catalyse et de l’ingénierie moléculaire enzymatiques (conception rationnelle et combinatoire d’enzymes performantes). Pierre Monsan est l'auteur de plus de 200 publications scientifiques, de deux ouvrages et de 56 brevets.

Pr Bernard Pau, Strategic Advisor of Deinove

Pr Bernard Pau, PhD in Immunology and in Biochemistry, is Professor of Pharmaceutical Sciences and entrepreneur, with over 25 years of experience in management of academic research, evaluation and innovation transfer to the industry. He was a member of the National Advisory Committee on Ethics between 2000 and 2004.
Bernard Pau is since 1983 Professor of Immunology and Biotechnology at the Faculty of Pharmacy (University of Montpellier). In 1992, he founded and headed for 10 year the Biotechnology and Pharmacology Institute, a joint-research unit of the CNRS and the industry, namely Sanofi then Biorad. Pr Pau also founded and managed, between 2000 and 2002, Innodia (Montreal), a company specialized in R&D in new therapeutic products againts Type II diabetes. Between 2002 et 2004, Bernard Pau has been Director of the Life Sciences Department of CNRS, then he founded the Institute for Therapeutic Innovation (I2T). Bernard Pau is the author of over 140 international articles and inventor of 9 patents during the last 10 year. He also developed 15 new diagnostic tests for the international market.